Regeneron Pharmaceuticals
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 1988-01-01
- Employees
- 13.4K
- Market Cap
- $132.4B
- Website
- http://www.regeneron.com
- Introduction
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy
- Conditions
- Cervical Cancer
- Interventions
- First Posted Date
- 2020-11-27
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 113
- Registration Number
- NCT04646005
- Locations
- πΊπΈ
Arizona Oncology Associates, Tucson, Arizona, United States
π§πͺUniversitair Ziekenhuis Gent, Gent, East Flanders, Belgium
π§πͺCHIREC Delta Hospital / Chirec Cancer Institute, Brussels, Belgium
CMP-001 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
- Conditions
- Squamous Cell Carcinoma of Head and Neck
- Interventions
- First Posted Date
- 2020-11-18
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT04633278
- Locations
- πΊπΈ
University of Chicago Medical Center, Chicago, Illinois, United States
πΊπΈUniversity of Southern California: Norris Oncology/Hematology - Newport Beach, Newport Beach, California, United States
πΊπΈUniversity of California - San Diego, La Jolla, California, United States
A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers
- Conditions
- Advanced Solid Tumors
- Interventions
- Drug: Platinum-based doublet chemotherapyDrug: Trifluridine-tipiracil
- First Posted Date
- 2020-11-12
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 933
- Registration Number
- NCT04626635
- Locations
- πͺπΈ
Hospital 12 de Octubre, Madrid, Spain
π³π±Netherlands Cancer Institute, Amsterdam, Netherlands
πΊπΈValkyrie Clinical Trials, Los Angeles, California, United States
Compassionate Use of REGN-COV2 for the Treatment of COVID-19
- Conditions
- COVID-19
- First Posted Date
- 2020-11-05
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- Regeneron Pharmaceuticals
- Registration Number
- NCT04617535
Study of the Safety, Tolerability, and Pharmacokinetics of REGN6490 in Healthy Japanese Adult Volunteers
- First Posted Date
- 2020-11-04
- Last Posted Date
- 2021-11-11
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 19
- Registration Number
- NCT04616105
- Locations
- πΊπΈ
Regeneron Study Site, Glendale, California, United States
Ascending Dose Study of the Safety and Tolerability of REGN6490 in Healthy Volunteers
- First Posted Date
- 2020-11-04
- Last Posted Date
- 2021-11-11
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 57
- Registration Number
- NCT04616079
- Locations
- π§πͺ
Regeneron Study Site, Ghent, Belgium
T Cell Receptor (TCR) Sequencing and Transcriptional Profiling in Adult Celiac Disease Patients Undergoing Gluten Challenge
- Conditions
- Celiac Disease
- Interventions
- Dietary Supplement: Gluten Powder
- First Posted Date
- 2020-11-04
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT04614571
- Locations
- πΊπΈ
Celiac Research Centre Mass General Hospital, Boston, Massachusetts, United States
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Pozelimab in Combination With Cemdisiran in Healthy Adult Volunteers
- First Posted Date
- 2020-10-26
- Last Posted Date
- 2021-11-12
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 19
- Registration Number
- NCT04601844
- Locations
- π§πͺ
Regeneron Research Site, Antwerp, Belgium
A Trial to Find Out How Safe REGN5668 is and How Well it Works When Given With Either Cemiplimab or REGN4018
- Conditions
- Ovarian CancerFallopian Tube CancerPrimary Peritoneal CancerEndometrial Cancer
- Interventions
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 612
- Registration Number
- NCT04590326
- Locations
- π«π·
Hopital Lyon Sud, Pierre-Benite, Lyon, France
π«π·Institut Gustave Roussy, Villejuif, France
πΊπΈThe City of Hope Orange County Lennar Foundation Cancer Center, Irvine, California, United States
Study to Assess the Efficacy and Safety of Garetosmab in Japanese Adult Patients With Fibrodysplasia Ossificans Progressiva (FOP)
- Conditions
- Fibrodyplasia Ossificans Progressiva (FOP)Heterotopic Ossification (HO)
- Interventions
- First Posted Date
- 2020-10-08
- Last Posted Date
- 2021-11-01
- Lead Sponsor
- Regeneron Pharmaceuticals
- Registration Number
- NCT04577820